Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MODEX2023 | Other Identifier | Clinical Trial Protocol Number | |
| FRN:183960 | Other Grant/Funding Number | CIHR | |
| CTO Project ID: 4701 | Other Identifier | Clinical Trials Ontario |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A stroke happens when blood flow to the brain is stopped and the brain gets damaged. At least half of people with a stroke have fatigue months and even years later. A lot of people report fatigue as one of the worst symptoms post stroke that can affect daily activities and the length and quality of life. Though all the reasons for fatigue after stroke and how to best treat it are not fully understood, the investigators think that fatigue results from the stroke changing the brain, reducing physical fitness, and decreasing muscle strength. A stroke can also affect sleep and mood, which can impact how people feel too. It is also not known why women experience more fatigue than men after a stroke.
Some studies have tested a drug called Modafinil for post stroke fatigue, while other studies have tested exercise for it. Yet, there is unclear evidence for either treatment, so this study has the following aim:
1. Test if Exercise plus Modafinil is better than Exercise plus a Sugar Pill
This study will take place at up to 6 Canadian research sites to give a good representation of people after a stroke. Each person will be tested on fatigue, mood, fitness, thinking skills, sleep, and usual activity levels.
Participants will be assigned at random (like flipping a coin) to 1 of 2 groups:
The treatment will last 8 weeks. The Modafinil or Sugar Pill will be taken once a day. The exercise will be delivered virtually by a trained therapist over computer to people at home 3 times a week. Change in fatigue, quality of life, and other outcomes will be measured over 6 months.
The investigators will assess the results to identify the best treatment for post stroke fatigue and hope to be able to find a treatment that will help reduce fatigue and improve quality of life after a stroke.
Study Rationale Post stroke fatigue (PSF) afflicts as many as 70% of the 400,000 Canadians with stroke. People with stroke endorse PSF as the most serious unmet research priority. Pathological fatigue is not relieved by rest and is characterized by persistent or extreme tiredness, exhaustion, and/or difficulty in initiating or sustaining voluntary activities. PSF is an excellent exemplar to study as the cause of disabling PSF is unclear. Systematic reviews confirm that PSF is multifactorial having both peripheral (e.g. cardiovascular and neuromuscular) and central (e.g. alterations in brain function resulting in both physical and psychological symptoms) components. There are no evidence-based treatments for PSF, however, exercise and the dopaminergic medication Modafinil that targets the dopaminergic movement circuits in the brain, have shown promise in alleviating symptoms in small studies.
Study Design This multicentre clinical trial will involve a double blind randomized controlled trial design to quantify the effect of a structured exercise program combined with Modafinil 200 mg daily or placebo medication over 8 weeks on severity of fatigue symptoms. It aims to recruit 212 participants into one of two arms. It will also explore the interactions of Modafinil in combination with exercise. The effects of mood, sleep, stroke impairments, sex, gender and activity levels on post stroke fatigue will also be explored.
Study Population Study participants must meet the inclusion/exclusion criteria at the time of entry into the study. In general, participants will be >3 months post stroke onset (i.e. intracerebral hemorrhage or ischemic stroke diagnosed by a physician) at the time of consent into the study.
Primary Hypothesis The primary hypothesis based on outcomes at 8 weeks is that structured telerehabilitation fitness and strengthening exercise plus Modafinil will improve fatigue symptom severity more than placebo medication and the same exercise.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Drug + Exercise | Placebo Comparator | Placebo Drug + Exercise for 8 weeks. |
|
| Modafinil 200 mg/day + Exercise | Active Comparator | Modafinil 200 mg/day + Exercise for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Modafinil 200mg | Drug | Modafinil 200mg daily for 8 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Severity of Fatigue Symptoms | Multidimensional Fatigue Inventory | Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Severity of Fatigue Symptoms | Multidimensional Fatigue Inventory | Week 4 and 26 |
| Impact on Quality of Life | Medical Outcomes Short Form Scale |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Josie Chundamala, MA, CCRP | Contact | 416-597-7015 | josie.chundamala@uhn.ca | |
| Olga Yaroslavtseva | Contact | 416-597-7015 | olga.yaroslavtseva@uhn.ca |
| Name | Affiliation | Role |
|---|---|---|
| Mark Bayley, MD, FRCPC | University Health Network, Toronto | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| D005221 | Fatigue |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077408 | Modafinil |
| D000073893 | Sugars |
| D015444 | Exercise |
| ID | Term |
|---|---|
| D001559 | Benzhydryl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
All members of the research team and the participants will be blinded to medication group allocation. The study statistician who is unblinded and the Data Safety Monitoring Board will have access to the medication assignment if needed (e.g. adverse drug reaction).
| Placebo | Drug | Placebo daily for 8 weeks. |
|
|
| Exercise | Behavioral | Exercise three times per week for 8 weeks. |
|
| Week 8 and 26 |
| Walking Recovery | Timed Up and Go | Week 8 and 26 |
| Leg Strength and Coordination | 30-Second Sit to Stand Test | Week 8 and 26 |
| 3-Day Physical Activity Assessment | Activity Accelerometer | Week 8 |
| Mood and Anxiety | Depression Anxiety Stress Scales | Week 4, 8, and 26 |
| Attention | Montreal Cognitive Assessment | Week 8 and 26 |
| Cognition | Trails Tests | Week 8 and 26 |
| Health Resource Utilization | Health Resource Utilization Questionnaire | Week 4, 8, and 26 |
| Quality Adjusted Life Years | Cost Per Quality Adjusted Life Years | Week 4, 8, and 26 |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D002241 | Carbohydrates |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |